The long journey from cell culture to a purified monoclonal antibody (mAb) involves many sample processing steps ... we'll explore these challenges and offer solutions for establishing a robust ...

In recent years, immunotherapeutic development has surged, with the use of immune B cells in hybridoma studies being the most robust method for monoclonal antibody (mAb) discovery. However, hybridoma ...

SUREmAb is a vertically integrated global offering designed to minimize development timelines for ... titers of up to 10 g/L with a lower-cost workflow to optimize operational efficiency and ...

The Biologics Development Workflow Biologic drugs are complex molecules derived ... the focus is on identifying and optimizing the biological molecule—usually a mAb or some antibody derivative.

Both PK and pharmacodynamic (PD) studies are necessary in the development of a new mAb drug candidate. Editor’s Note: This article was published in Pharmaceutical Technology Europe’s December 2022 ...

Cancer immunotherapy biotech I-Mab, has paused the development of uliledlimab in favour of its now lead candidate givastomig. The Maryland, US-based company saw an uptick in its stock price on 6 ...

If neither Congress nor the White House are willing to encourage variant-specific mAb development, then FDA should minimize biopharmaceutical companies’ regulatory risk. The agency has the ...